Perspectives in Psychiatric Care / 2023 / Article / Tab 2 / Research Article
Importance of Long-Acting Injectable Antipsychotic Preparation, Administration, and Injection Site Tolerability: A Focus on Paliperidone Palmitate Once-Every-6-Months Formulation Table 2 Investigator evaluation of injection sites during the double-blind phase.
Patients, n (%) PP6M PP3M Baseline, n = 478 End point, n = 477 Baseline, n = 224 End point, n = 223 Total High dose Moderate dose Total High dose Moderate dose Total High dose Moderate dose Total High dose Moderate dose Erythema/redness N 478 248 230 477 248 229 224 118 106 223 118 105 Absent 473 (99.0) 245 (98.8) 228 (99.1) 476 (99.8) 247 (99.6) 229 (100) 222 (99.1) 117 (99.2) 105 (99.1) 222 (99.6) 117 (99.2) 105 (100) Mild 5 (1.0) 3 (1.2) 2 (0.9) 1 (0.2) 1 (0.4) 0 2 (0.9) 1 (0.8) 1 (0.9) 1 (0.4) 1 (0.8) 0 Induration/swelling n 478 248 230 477 248 229 224 118 106 223 118 105 Absent 469 (98.1) 242 (97.6) 227 (98.7) 475 (99.6) 247 (99.6) 228 (99.6) 220 (98.2) 116 (98.3) 104 (98.1) 222 (99.6) 117 (99.2) 105 (100) Mild 9 (1.9) 6 (2.4) 3 (1.3) 2 (0.4) 1 (0.4) 1 (0.4) 4 (1.8) 2 (1.7) 2 (1.9) 1 (0.4) 1 (0.8) 0 Tenderness n 478 248 230 477 248 229 224 118 106 223 118 105 Absent 425 (88.9) 218 (87.9) 207 (90.0) 474 (99.4) 246 (99.2) 228 (99.6) 207 (92.4) 111 (94.1) 96 (90.6) 221 (99.1) 117 (99.2) 104 (99.0) Mild 48 (10.0) 28 (11.3) 20 (8.7) 3 (0.6) 2 (0.8) 1 (0.4) 16 (7.1) 6 (5.1) 10 (9.4) 2 (0.9) 1 (0.8) 1 (1.0) Moderate 5 (1.0) 2 (0.8) 3 (1.3) — — — 1 (0.4) 1 (0.8) 0 — — —
Note. PP3M, paliperidone palmitate once-every-3-months; PP6M, paliperidone palmitate once-every-6-months.